Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis

Comoglio, 2008, Drug development of MET inhibitors: targeting oncogene addiction and expedience, Nat. Rev. Drug. Discovery, 7, 504, 10.1038/nrd2530 Gherardi, 2012, Targeting MET in cancer: rationale and progress, Nat. Rev. Cancer, 12, 10.1038/nrc3367 Straussman, 2012, Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion, Nature, 487, 500, 10.1038/nature11183 Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478 Blumenschein, 2012, Targeting the hepatocyte growth factor-cMET axis in cancer therapy, J. Clin. Oncol., 30, 3287, 10.1200/JCO.2011.40.3774 Feldman, 2013, A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors, Invest. New. Drugs, 31, 1016, 10.1007/s10637-013-9934-y Hussain, 2011, Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial, J. Clin. Oncol., 29, 10.1200/jco.2011.29.15_suppl.4516 Schiering, 2003, Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a, Proc. Natl. Acad. Sci., 100, 12654, 10.1073/pnas.1734128100 Albrecht, 2008, Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase, J. Med. Chem., 51, 2879, 10.1021/jm800043g Chen, 2012, O-Linked triazolotriazines: potent and selective c-met inhibitors, Chem. Med. Chem., 7, 1276, 10.1002/cmdc.201200145 D'Angelo, 2008, Design, synthesis, and biological evaluation of potent c-Met inhibitors, J. Med. Chem., 51, 5766, 10.1021/jm8006189 Liu, 2012, Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the Pyrazolone series, J. Med. Chem., 55, 1868, 10.1021/jm201331s Norman, 2012, Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives, J. Med. Chem., 55, 1858, 10.1021/jm201330u Nishii, 2010, Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors, Bioorg. Med. Chem. Lett., 20, 1405, 10.1016/j.bmcl.2009.12.109 Wang, 2011, Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent, J. Med. Chem., 54, 2127, 10.1021/jm101340q Ye, 2013, Indazoles as potential c-met inhibitors: design, synthesis and molecular docking studies, Eur. J. Med. Chem., 65, 112, 10.1016/j.ejmech.2013.04.004 Schroeder, 2009, Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily, J. Med. Chem., 52, 1251, 10.1021/jm801586s Cui, 2011, Structure based drug design of Crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK), J. Med. Chem., 54, 6342, 10.1021/jm2007613 Cui, 2013, J. Med. Chem., 56, 6651, 10.1021/jm400926x Li, 2013, Aminopyridyl/Pyrazinyl Spiro[indoline-3,4′-piperidine]-2-ones as highly selective and efficacious c-Met/ALK inhibitors, ACS. Med. Chem. Lett., 4, 806, 10.1021/ml400203d Katz, 2011, Discovery of a 5H-Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer, J. Med. Chem., 54, 4092, 10.1021/jm200112k Northrup, 2013, Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): a specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met, J. Med. Chem., 56, 2294, 10.1021/jm301619u Milkiewicz, 2011, Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group, Bioorg. Med. Chem., 19, 6274, 10.1016/j.bmc.2011.09.006 Weinberg, 2011, Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors, Bioorg. Med. Chem. Lett., 21, 164, 10.1016/j.bmcl.2010.11.045 Zificsak, 2011, 2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines, Bioorg. Med. Chem. Lett., 21, 660, 10.1016/j.bmcl.2010.12.013 Ye, 2012, Design and synthesis of some novel 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indoles as potential c-Met inhibitors, Helv. Chim. Acta, 95, 320, 10.1002/hlca.201100226 Liang, 2012, Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay, Org. Biomol. Chem., 10, 421, 10.1039/C1OB06186K Porter, 2009, Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase, Bioorg. Med. Chem. Lett., 19, 397, 10.1016/j.bmcl.2008.11.062 Abidoye, 2007, Review of clinic trials: agents targeting c-met, Rev. Recent Clin. Trials, 2, 143, 10.2174/157488707780599357 Comoglio, 2008, Drug development of MET inhibitors: targeting oncogene addiction and expedience, Nat. Rev. Drug Discovery, 7, 504, 10.1038/nrd2530 Eder, 2009, Novel therapeutic inhibitors of the c-Met signaling pathway in Cancer, Clin. Cancer Res., 15, 2207, 10.1158/1078-0432.CCR-08-1306 http://clinicaltrials.gov/ct2/results?term=c-Met. Liao, 2007, Molecular Recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors, J. Med. Chem., 50, 409, 10.1021/jm0608107 Dussault, 2009, From concept to reality: the long road to c-Met and ron receptor tyrosine kinase inhibitors for the treatment of cancer, Anti-Cancer Agents Med. Chem., 9, 221, 10.2174/187152009787313792 Cui, 2007, Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications, Expert Opin. Ther. Pat., 17, 1035, 10.1517/13543776.17.9.1035 Gentile, 2008, The Met tyrosine kinase receptor in development and cancer, Cancer Metastasis Rev., 27, 85, 10.1007/s10555-007-9107-6 Porter, 2010, Small molecule c-Met kinase inhibitors: a review of recent patents, Expert Opin. Ther. Pat., 20, 159, 10.1517/13543770903514137 Underiner, 2010, Discovery of small molecule c-met inhibitors: evolution and profiles of clinical candidates, Anti-Cancer Agents Med. Chem., 10, 7, 10.2174/1871520611009010007 Lin, 2007, Microwave-enhanced efficient synthesis of diversified 3,6-disubstituted pyridazines, J. Comb. Chem., 9, 742, 10.1021/cc070046p A. Blaukat, D. Dorsch, O. Schadt, F. Stieber, New pyridazinone Derivatives are Met Kinase Inhibitors Useful to Treat e.g. Solid Tumor, Angiogenesis, Arteriosclerosis, Age-Related Macular Degeneration, Choroidal Neovascularization, Diabetic Retinopathy, and Inflammatory Diseases, WO2010078910. D. Dorsch, O. Schadt, A. Blaukat, New 1-Substituted-6-Oxo-Pyridazine Derivatives, Useful for Treating e.g. Tumors, Diabetic Retinopathy and Inflammation, Act by Inhibiting Signal Transduction Through Kinases, WO2007065518. D. Dorsch, F. Stieber, O. Schadt, A. Blaukat, New Compound for Producing Drug for Treating Diseases as Tumor of Blood and Immune System and Solid Tumor, e.g. Tumor of Squamous Epithelium, Acute Lymphatic Leukemia or Chronic Lymphatic Leukemia, is Produced by Reacting Compound, WO2009006959 Bladt, 2013, EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors, Clin. Cancer. Res., 19, 2941, 10.1158/1078-0432.CCR-12-3247 Schadt, 2010, Preclinical characterization of EMD 1214063-a selective c-Met kinase inhibitor in clinical phase 1, EJC Suppl., 8, 10.1016/S1359-6349(10)71921-2 Ye, 2013, Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors, J. Med. Chem., 56, 2885, 10.1021/jm301825t Kim, 2008, Discovery of pyrrolopyridine–pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities, J. Med. Chem., 51, 5330, 10.1021/jm800476q Cai, 2008, Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors, Bioog. Med. Chem. Lett., 18, 3224, 10.1016/j.bmcl.2008.04.047 Williams, 2010, Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors, Bioog. Med. Chem. Lett., 20, 2998, 10.1016/j.bmcl.2010.01.042 Swinney, 2004, Biochemical mechanisms of drug action: what does it take for success?, Nat. Rev. Drug Discovery, 3, 801, 10.1038/nrd1500 Copeland, 2006, Drug–target residence time and its implications for lead optimization, Nat. Rev. Drug Discovery, 7, 730, 10.1038/nrd2082 Taft, 2008, Current topics in computer-aided drug design, J. Pharm. Sci., 97, 1089, 10.1002/jps.21293 Copeland, 2010, The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety, Expert Opin. Drug Discovery, 5, 305, 10.1517/17460441003677725 Bai, 2013, Free energy landscape for the binding process of Huperzine A to acetylcholinesterase, P. Natl. Acad. Sci., 110, 4273, 10.1073/pnas.1301814110